Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a ...

Tonix Pharmaceuticals (TNXP) announced the launch of TONIX ONE, a fully-integrated digital platform designed to help patients better understand ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 11.27%, which has investors questioning if this is right time to buy.

The biotechnology sector has experienced a jolt of volatility over the past few days, spearheaded by the dramatic price ...

Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) plummeted 19% lower on Wednesday noon after the company reported fourth-quarter revenue and earnings below estimates. The biopharmaceutical company ...

Tonix Pharmaceuticals shares are trading higher by 22.5% during Monday's session. The company announced that the FDA will not ...

Shares of Tonix Pharmaceuticals are pulling back 12.7% during Thursday's session. The stock is pulling back following a regulatory update on its experimental fibromyalgia treatment, TNX-102 SL.

Clade I, the culprit in the current 2025 version of global epidemic mpox, is highly transmissible and is spreading within ...

FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has surged by 26.61%, which has investors questioning if this is right ...

A copy of the Company’s poster will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be ...

Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, emphasized the company’s innovative efforts to improve patient access to necessary medications. He stated that TONIX ONE ...